title: Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease.
abstract: OBJECTIVE
  The purpose of this study was to investigate the effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein [hs-CRP], interleukin-6 [IL-6], and homocysteine) in patients with coronary artery disease (CAD).
  
  
  METHODS
  Patients with CAD (n = 51) were randomly assigned to a placebo group (n = 14) or one of two coenzyme Q10-supplemented groups (60 mg/d, Q10-60 group, n = 19; 150 mg/d, Q10-150 group, n = 18). The intervention was administered for 12 wk. Plasma coenzyme Q10 concentration, inflammatory markers (hs-CRP, IL-6, and homocysteine), malondialdehyde, and superoxide dismutase activities were measured.
  
  
  RESULTS
  Forty subjects with CAD completed the intervention study. The plasma coenzyme Q10 concentration increased significantly in the Q10-60 and Q10-150 groups (P < 0.01). After 12 wk of intervention, the inflammatory marker IL-6 (P = 0.03) was decreased significantly in the Q10-150 group. Subjects in the Q10-150 group had significantly lower malondialdehyde levels and those in the Q10-60 (P = 0.05) and Q10-150 (P = 0.06) groups had greater superoxide dismutase activities. Plasma coenzyme Q10 was inversely correlated with hs-CRP (r = -0.20, P = 0.07) and IL-6 (r = -0.25, P = 0.03) at baseline. After supplementation, plasma coenzyme Q10 was significantly correlated with malondialdehyde (r = -0.35, P < 0.01) and superoxide dismutase activities (r = 0.52, P < 0.01). However, there was no correlation between coenzyme Q10 and homocysteine.
  
  
  CONCLUSIONS
  Coenzyme Q10 supplementation at a dosage of 150 mg appears to decrease the inflammatory marker IL-6 in patients with CAD.
authors.affiliation: School of Nutrition, Chung Shan Medical University, Taichung, Taiwan.
authors.forename: Bor-Jen
authors.initials: BJ
authors.lastname: Lee
authors.forename: Yi-Chia
authors.initials: YC
authors.lastname: Huang
authors.forename: Shu-Ju
authors.initials: SJ
authors.lastname: Chen
authors.forename: Ping-Ting
authors.initials: PT
authors.lastname: Lin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis*; D003324:Coronary Artery Disease / Q000097:blood / Q000178:diet therapy* / Q000276:immunology; D019587:Dietary Supplements; D005260:Female; D006710:Homocysteine / Q000097:blood; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D010352:Patient Dropouts; D013482:Superoxide Dismutase / Q000097:blood; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; C508600:IL6 protein, human; D018836:Inflammation Mediators; D015850:Interleukin-6; D006710:Homocysteine; D014451:Ubiquinone; D008315:Malondialdehyde; D002097:C-Reactive Protein; D013482:Superoxide Dismutase; C024989:coenzyme Q10